Article Versions Notes

Grosjean HAI, Dolter S, Meyers DE, Ding PQ, Stukalin I, Goutam S, Kong S, Chu Q, Heng DYC, Bebb DG, et al. Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database. Current Oncology. 2021; 28(5):4213-4222. https://doi.org/10.3390/curroncol28050357

Grosjean, Heidi A. I., Samantha Dolter, Daniel E. Meyers, Philip Q. Ding, Igor Stukalin, Siddhartha Goutam, Shiying Kong, Quincy Chu, Daniel Y. C. Heng, D. Gwyn Bebb, and et al. 2021. "Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database" Current Oncology 28, no. 5: 4213-4222. https://doi.org/10.3390/curroncol28050357

Grosjean, H. A. I., Dolter, S., Meyers, D. E., Ding, P. Q., Stukalin, I., Goutam, S., Kong, S., Chu, Q., Heng, D. Y. C., Bebb, D. G., Morris, D. G., Cheung, W. Y., & Pabani, A. (2021). Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database. Current Oncology, 28(5), 4213-4222. https://doi.org/10.3390/curroncol28050357